These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36878909)

  • 1. ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease.
    Stecklein SR; Kimler BF; Yoder R; Schwensen K; Staley JM; Khan QJ; O'Dea AP; Nye LE; Elia M; Heldstab J; Home T; Hyter S; Isakova K; Pathak HB; Godwin AK; Sharma P
    NPJ Breast Cancer; 2023 Mar; 9(1):10. PubMed ID: 36878909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
    Parsons HA; Blewett T; Chu X; Sridhar S; Santos K; Xiong K; Abramson VG; Patel A; Cheng J; Brufsky A; Rhoades J; Force J; Liu R; Traina TA; Carey LA; Rimawi MF; Miller KD; Stearns V; Specht J; Falkson C; Burstein HJ; Wolff AC; Winer EP; Tayob N; Krop IE; Makrigiorgos GM; Golub TR; Mayer EL; Adalsteinsson VA
    Ann Oncol; 2023 Oct; 34(10):899-906. PubMed ID: 37597579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
    Parsons HA; Blewett T; Chu X; Sridhar S; Santos K; Xiong K; Abramson VG; Patel A; Cheng J; Brufsky A; Rhoades J; Force J; Liu R; Traina TA; Carey LA; Rimawi MF; Miller KD; Stearns V; Specht J; Falkson C; Burstein HJ; Wolff AC; Winer EP; Tayob N; Krop IE; Makrigiorgos GM; Golub TR; Mayer EL; Adalsteinsson VA
    medRxiv; 2023 Mar; ():. PubMed ID: 36945501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
    Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
    Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.
    Zhou Q; Gampenrieder SP; Frantal S; Rinnerthaler G; Singer CF; Egle D; Pfeiler G; Bartsch R; Wette V; Pichler A; Petru E; Dubsky PC; Bago-Horvath Z; Fesl C; Rudas M; Ståhlberg A; Graf R; Weber S; Dandachi N; Filipits M; Gnant M; Balic M; Heitzer E
    Clin Cancer Res; 2022 Feb; 28(4):697-707. PubMed ID: 34862246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
    Hamy AS; Darrigues L; Laas E; De Croze D; Topciu L; Lam GT; Evrevin C; Rozette S; Laot L; Lerebours F; Pierga JY; Osdoit M; Faron M; Feron JG; Laé M; Reyal F
    PLoS One; 2020; 15(6):e0234191. PubMed ID: 32579551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
    J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
    Takahashi Y; Iwamoto T; Suzuki Y; Kajiwara Y; Hatono M; Tsukioki T; Kawada K; Kochi M; Ikeda H; Shien T; Taira N; Matsuoka J; Doihara H; Toyooka S
    Clin Breast Cancer; 2020 Apr; 20(2):117-124.e4. PubMed ID: 31570267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF; Yau C; Chen YY; Balassanian R; Klein ME; Pusztai L; Nanda R; Parker BA; Datnow B; Krings G; Wei S; Feldman MD; Duan X; Chen B; Sattar H; Khazai L; Zeck JC; Sams S; Mhawech-Fauceglia P; Rendi M; Sahoo S; Ocal IT; Fan F; LeBeau LG; Vinh T; Troxell ML; Chien AJ; Wallace AM; Forero-Torres A; Ellis E; Albain KS; Murthy RK; Boughey JC; Liu MC; Haley BB; Elias AD; Clark AS; Kemmer K; Isaacs C; Lang JE; Han HS; Edmiston K; Viscusi RK; Northfelt DW; Khan QJ; Leyland-Jones B; Venters SJ; Shad S; Matthews JB; Asare SM; Buxton M; Asare AL; Rugo HS; Schwab RB; Helsten T; Hylton NM; van 't Veer L; Perlmutter J; DeMichele AM; Yee D; Berry DA; Esserman LJ
    JAMA Oncol; 2021 Nov; 7(11):1654-1663. PubMed ID: 34529000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
    Du L; Yau C; Brown-Swigart L; Gould R; Krings G; Hirst GL; Bedrosian I; Layman RM; Carter JM; Klein M; Venters S; Shad S; van der Noordaa M; Chien AJ; Haddad T; Isaacs C; Pusztai L; Albain K; Nanda R; Tripathy D; Liu MC; Boughey J; Schwab R; Hylton N; DeMichele A; Perlmutter J; Yee D; Berry D; Van't Veer L; Valero V; Esserman LJ; Symmans WF
    Ann Oncol; 2021 May; 32(5):642-651. PubMed ID: 33617937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
    Lin PH; Wang MY; Lo C; Tsai LW; Yen TC; Huang TY; Huang WC; Yang K; Chen CK; Fan SC; Kuo SH; Huang CS
    Front Oncol; 2021; 11():736769. PubMed ID: 34868925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy.
    Elder EA; Livasy CA; Donahue EE; Neelands B; Patrick A; Needham M; Sarantou T; Hadzikadic-Gusic L; Heeke AL; White RL
    Ann Surg Oncol; 2022 Dec; 29(13):8060-8069. PubMed ID: 35980548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
    Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
    Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
    Turner NC; Swift C; Jenkins B; Kilburn L; Coakley M; Beaney M; Fox L; Goddard K; Garcia-Murillas I; Proszek P; Hall P; Harper-Wynne C; Hickish T; Kernaghan S; Macpherson IR; Okines AFC; Palmieri C; Perry S; Randle K; Snowdon C; Stobart H; Wardley AM; Wheatley D; Waters S; Winter MC; Hubank M; Allen SD; Bliss JM;
    Ann Oncol; 2023 Feb; 34(2):200-211. PubMed ID: 36423745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
    Symmans WF; Peintinger F; Hatzis C; Rajan R; Kuerer H; Valero V; Assad L; Poniecka A; Hennessy B; Green M; Buzdar AU; Singletary SE; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2007 Oct; 25(28):4414-22. PubMed ID: 17785706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
    Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
    Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity.
    Suppan C; Posch F; Mueller HD; Mischitz N; Steiner D; Klocker EV; Setaffy L; Bargfrieder U; Hammer R; Hauser H; Jost PJ; Dandachi N; Lax S; Balic M
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.